UCB forecasts earnings growth after 2015 beat

February 26, 2016 6:26 AM

1 0

BRUSSELS Feb 26 Belgian pharmaceutical group UCB forecast further expansion of revenue and profit this year after its three newer drugs drove earnings by more than expected in 2016.

The company, which specialises in the central nervous system and immunology, said it expected revenue next year to between 4.0 and 4.1 billion euros, recurring core profit (EBITDA) of 0.97-1.01 billion euros and core earnings per share of 2.90-3.20 euros.

Also read: China Growth Holds at 6.7%, Backed by Government and Consumers

Read more

To category page